A specialist clinic for the prescription of medical cannabis in Melbourne, Australia.
Treating Multiple Sclerosis (MS) with Medical Cannabis
Treatments tailored to you
Affecting over 25,000 Australians, Multiple Sclerosis (MS) is a nervous condition that causes a range of symptoms, from involuntary arm or leg movements to issues with vision, balance and sensation. It can present as an individual relapse with an attack or gradual degeneration.
While there is currently no cure for MS, medical practitioners focus on treating individual symptoms and slowing the progression of the disease.
Recovery times from relapses can be decreased with steroid medication to reduce nerve inflammation, and the side effects typically range from increased blood pressure through to mood swings. Relapsing-remitting MS treatments include beta-interferon injections to reduce relapse frequency, oral medications and infusion treatments.
Medicinal Cannabis and MS
The Endocannabinoid system (ECS) is a widespread network of receptors throughout the body that play a critical role in regulating many physiological systems, including signals between the brain and the muscles. Cannabinoids are the active chemical compounds in cannabis. These naturally occurring compounds have been proven to interact directly with receptors in the ECS.
There are over 100 cannabinoids in medical cannabis, and two in particular have been isolated and widely researched with regards to their impact on MS symptoms, Tetrahydrocannabinol (THC) and oral cannabis extract (OCE).
In a 2014 study, both THC and OCE were found to reduce pain or painful muscle spasms1. This work supported an earlier UK investigation that concluded that OCE could be used to effectively treat muscle stiffness in MS2. More recently, progressive MS patients treated with a THC product reported significantly reduced pain and muscle spasticity3. But that’s not to say these are the only cannabinoids that can help to relieve MS symptoms. Cannabidiol (CBD) is another well researched cannabinoid originating in the marijuana plant. Like THC, there is a strong evidence to suggest it interacts with cannabinoid receptors throughout the body and can provide relief from certain MS symptoms. A combined treatment of CBD and THC has been shown to improve muscle spasms in just four weeks3, while CBD oils are popular among MS patients for topical application.
Supporting MS Patients at MediCannabis
The cannabinoids in medical cannabis have been shown to be effective natural remedies for conditions including chronic pain and muscle spasms. As such, the field of medical cannabis represents a growing range of alternative treatments for MS patients.
At MediCannabis, we are committed to helping you find treatments that work for you. To seek guidance on how cannabis can be used to help alleviate your MS symptoms, please book an appointment today.
To book an appointment at our medical cannabis clinic in Port Melbourne, Victoria, please follow the link below.
If you would like more information, or if you have any questions about cannabinoid treatments for multiple sclerosis, please call reception on (03) 9676 8888.
1 Koppel, B.S et al. 2014. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 82(17), pp, 1556-1563.
2 Zajicek, J.P. et al., 2012. MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. 83. pp 1125-1132.
3 Van Amerongen, G., et al., 2018. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. Clinical Therapeutics, 40(9). pp 1467-1482.
4 Syed, YY., McKeage, K., and Scott, L.J. 2014. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs, 74(5). pp. 563-78.
More Information on Medical Cannabis for Multiple Sclerosis in Australia
Multiple Sclerosis (MS)
Official Medical Cannabis Guidance on Multiple Sclerosis from the Therapeutic Goods Association (TGA) of Australia